These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37879381)

  • 1. Evaluation of MADIT-II Risk Stratification Score Among Nationwide Registry of Heart Failure Patients With Primary Prevention Implantable Cardiac Defibrillators or Resynchronization Therapy Devices.
    Rav-Acha M; Wube O; Brodie OT; Michowitz Y; Ilan M; Ovdat T; Klempfner R; Suleiman M; Goldenberg I; Glikson M
    Am J Cardiol; 2024 Jan; 211():17-28. PubMed ID: 37879381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival and arrhythmic risk among ischemic and non-ischemic heart failure patients with prophylactic implantable cardioverter defibrillator only therapy: A propensity score-matched analysis.
    Briongos-Figuero S; Estévez A; Luisa Pérez M; Martínez-Ferrer JB; García E; Viñolas X; Arenal Á; Alzueta J; Basterra N; Rodríguez A; Lozano I; Muñoz-Aguilera R
    Int J Cardiol; 2019 Jan; 274():163-169. PubMed ID: 30206014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score.
    Younis A; Goldberger JJ; Kutyifa V; Zareba W; Polonsky B; Klein H; Aktas MK; Huang D; Daubert J; Estes M; Cannom D; McNitt S; Stein K; Goldenberg I
    Eur Heart J; 2021 May; 42(17):1676-1684. PubMed ID: 33417692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MADIT-ICD benefit score helps to select implantable cardioverter-defibrillator candidates in cardiac resynchronization therapy.
    Dauw J; Martens P; Nijst P; Meekers E; Deferm S; Gruwez H; Rivero-Ayerza M; Van Herendael H; Pison L; Nuyens D; Dupont M; Mullens W
    Europace; 2022 Sep; 24(8):1276-1283. PubMed ID: 35352116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry.
    Amit G; Suleiman M; Konstantino Y; Luria D; Kazatsker M; Chetboun I; Haim M; Gavrielov-Yusim N; Goldenberg I; Glikson M;
    Europace; 2014 Aug; 16(8):1175-80. PubMed ID: 24554524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus.
    Sharma A; Wu J; Xu H; Hernandez A; Felker GM; Al-Khatib S; Green J; Matsouaka R; Fonarow GC; Singh JP; Heidenreich PA; Ezekowitz JA; DeVore A
    J Am Heart Assoc; 2020 Jun; 9(12):e012405. PubMed ID: 32476539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients.
    Bilchick KC; Wang Y; Curtis JP; Cheng A; Dharmarajan K; Shadman R; Dardas TF; Anand I; Lund LH; Dahlström U; Sartipy U; Maggioni A; O'Connor C; Levy WC
    Am Heart J; 2020 Apr; 222():93-104. PubMed ID: 32032927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure.
    Fudim M; Ali-Ahmed F; Parzynski CS; Ambrosy AP; Friedman DJ; Pokorney SD; Curtis JP; Fonarow GC; Masoudi FA; Hernandez AF; Al-Khatib SM
    JAMA Cardiol; 2020 Jun; 5(6):643-651. PubMed ID: 32211811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.
    Klein H; Auricchio A; Reek S; Geller C
    Am J Cardiol; 1999 Mar; 83(5B):91D-97D. PubMed ID: 10089848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes after prophylactic ICD and CRT-D implantation in nonischemic patients: Analysis from a nationwide database of daily remote-monitoring transmissions.
    Forleo GB; Solimene F; Pisanò EC; Zanotto G; Calvi V; Pignalberi C; Maglia G; Iacopino S; Quartieri F; Biffi M; Caravati F; Curnis A; Capucci A; Senatore G; Santamaria M; Della Bella P; Manzo M; Giacopelli D; Gargaro A; D'Onofrio A
    J Cardiovasc Electrophysiol; 2019 Sep; 30(9):1626-1635. PubMed ID: 31165517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes.
    Sharma A; Al-Khatib SM; Ezekowitz JA; Cooper LB; Fordyce CB; Michael Felker G; Bardy GH; Poole JE; Thomas Bigger J; Buxton AE; Moss AJ; Friedman DJ; Lee KL; Steinman R; Dorian P; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Peterson ED; Inoue LYT; Sanders GD
    Eur J Heart Fail; 2018 Jun; 20(6):1031-1038. PubMed ID: 29761861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Ventricular Tachyarrhythmic Events in Patients Who Improved Beyond Guidelines for a Defibrillator in MADIT-CRT.
    Sherazi S; Shah F; Kutyifa V; McNitt S; Aktas MK; Polonsky B; Zareba W; Goldenberg I
    JACC Clin Electrophysiol; 2019 Oct; 5(10):1172-1181. PubMed ID: 31648742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival Probability and Survival Benefit Associated With Primary Prevention Implantable Cardioverter-Defibrillator Generator Changes.
    Bilchick KC; Wang Y; Curtis JP; Shadman R; Dardas TF; Anand I; Lund LH; Dahlström U; Sartipy U; Levy WC
    J Am Heart Assoc; 2022 Jul; 11(13):e023743. PubMed ID: 35766293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial.
    Ruwald MH; Solomon SD; Foster E; Kutyifa V; Ruwald AC; Sherazi S; McNitt S; Jons C; Moss AJ; Zareba W
    Circulation; 2014 Dec; 130(25):2278-86. PubMed ID: 25301831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation.
    Colquitt JL; Mendes D; Clegg AJ; Harris P; Cooper K; Picot J; Bryant J
    Health Technol Assess; 2014 Aug; 18(56):1-560. PubMed ID: 25169727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry.
    Schrage B; Uijl A; Benson L; Westermann D; Ståhlberg M; Stolfo D; Dahlström U; Linde C; Braunschweig F; Savarese G
    Circulation; 2019 Nov; 140(19):1530-1539. PubMed ID: 31476893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arrhythmic burden among asymptomatic patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator.
    Sabbag A; Glikson M; Suleiman M; Boulos M; Goldenberg I; Beinart R; Nof E
    Heart Rhythm; 2019 Jun; 16(6):813-819. PubMed ID: 31153454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac Resynchronization Therapy Reduces Ventricular Arrhythmias in Primary but Not Secondary Prophylactic Implantable Cardioverter Defibrillator Patients: Insight From the Resynchronization in Ambulatory Heart Failure Trial.
    Sapp JL; Parkash R; Wells GA; Yetisir E; Gardner MJ; Healey JS; Thibault B; Sterns LD; Birnie D; Nery PB; Sivakumaran S; Essebag V; Dorian P; Tang AS
    Circ Arrhythm Electrophysiol; 2017 Mar; 10(3):. PubMed ID: 28292754
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.